Category Archives: Stem Cell Medicine


Her own stem cells saved her from hip replacement

Apollo Health City team did autologous stem cell procedure to save both the hip joints

Hyderabad, June 30:

A team of doctors from a city hospital have harvested stem cells of a person using bone morrow from the pelvis area to replace some dead tissues in the hip. In this process, they saved the patient from undergoing a hip replacement.

The Apollo Health City team, headed by orthopaedic specialist Paripati Sharat Kumar, diagnosed a 39-year-old woman to be suffering from Avascular Necrosis, making her writhe with pain in her two hip joints. Her condition would require undergoing a replacement of hips.

After assessing her condition, the team has decided to go for autologous stem cell procedure (where donor and the receiver is the same person) to save both the hip joints.

The minimally invasive procedure involved taking bone marrow aspirate from the patients pelvis. Stem cells were harvested from the aspirate, through a process that takes about 15 minutes. Stems cells were planted in the area of damage under fluoroscopy control following core decompression, Sharat Kumar said here in a statementon Monday.

He felt that autologous stem cell treatments could edge out joint replacement procedures to a large extent in days to come. The scope of this procedure in orthopaedics and sports medicine is enormous. This could be extended to indications include osteoarthritis of knee, shoulder, hip, elbows, ankle and spine, he said.

(This article was published on June 30, 2014)

Link:
Her own stem cells saved her from hip replacement

Regenerative Medicine Solutions Acquires Advanced Healthcare Partners

Tampa, FL (PRWEB) June 27, 2014

Furthering its goal to restore quality of life to patients with little or no hope of medical improvement, Regenerative Medicine Solutions (RMS) announced today that it has entered into an agreement to acquire Advanced Healthcare Partners (AHP). The strategy behind the business move was the realignment of resources, and the innovative use of stem cells to treat an array of medical conditions under one roof. AHP was a leading healthcare management and consulting company, which owned and operated the Lung Institute.

We are now ready to continue growing the Lung Institute to be the world leader in the care of patients suffering from lung disease by providing the best option for their treatment, said Jimmy St. Louis, Chief Executive Officer of RMS. In order to accomplish this mission, we needed to combine all of our teammates and resources together to focus on one company and one mission, RMS.

As a leader in regenerative medicine, the Lung Institute utilizes stem cells from the patients own body to treat lung disease. These autologous cells work to promote the repair and regeneration of previously damaged lung tissue. RMS is a global provider of stem cell therapy for medical conditions in areas of the body other than the lung.

All AHP and Lung Institute 31 employees are now considered employees of RMS, added St. Louis. With everyone together as one cohesive team, we have tripled our number. We are one team, with one goal: utilization of regenerative medicine to improve the quality of life of our patients from COPD to Crohns disease and beyond.

Together, RMS and the Lung Institute will offer patients access to better care with a staff dedicated to one goal: Improving quality of life in patients. Financial terms of the agreement were not disclosed. RMS has facilities in Tampa and Lima, Peru.

About Regenerative Medicine Solutions Regenerative Medicine Solutions (RMS) is a leading global provider of innovative regenerative technologies in order to treat an array of debilitating medical conditions. Committed to an individualized patient-centric approach, RMS consistently provides the highest quality of care while producing positive outcomes. By applying modern-day best practices to the growing field of regenerative medicine, RMS is changing lives. For more information, visit our website at myregenmed.com, like us on Facebook, or follow us on Twitter or call us today at 1-855-469-5864.

About Lung Institute Located in Tampa, Florida, the Lung Institute is changing the lives of hundreds of people across the world through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at 1-855-4MY-LUNG.

Original post:
Regenerative Medicine Solutions Acquires Advanced Healthcare Partners

New Stem Cell Production Method Could Clear Way for Anticancer Gene Therapy

Durham, NC (PRWEB) June 27, 2014

A new study released today in STEM CELLS Translational Medicine suggests a new way to produce endothelial progenitor cells in quantities large enough to be feasible for use in developing new cancer treatments.

Endothelial progenitor cells (EPCs) are rare stem cells that circulate in the blood with the ability to differentiate into the cells that make up the lining of blood vessels. With an intrinsic ability to home to tumors, researchers have focused on them as a way to deliver gene therapy straight to the cancer. However, the challenge has been to collect enough EPCs for this use.

This new study, by researchers at the Institute of Bioengineering and Nanotechnology, National University of Singapore and Zhejiang University led by Shu Wang, Ph.D., explored whether human induced pluripotent stem cells (iPSCs) could provide the answer. iPSCs, generated from adult cells, can propagate indefinitely and give rise to every other cell type in the body, much like human embryonic stem cells, which are considered the gold standard for stem cell therapy.

However, human iPS cells can be generated relatively easily through reprogramming, a procedure that circumvents the bioethical controversies associated with deriving embryonic stem cells from human embryos, Dr. Wang said.

After inducing human iPS cells to differentiate into the EPCs, the research team compared the stability and reliability of the induced EPCs with regular EPCs by injecting them into mice with breast cancer that had metastasized (traveled) to the lungs. The results showed that their induced EPCs retained the intrinsic ability to home to tumors, just as regular EPCs do. They also did not promote tumor growth or metastasis.

We next tested the induced EPCs therapeutic potential by infusing them with an anticancer gene and injecting them into the mice, Dr. Wang said. The results indicated that the tumors were reduced and the animals survival rates increased.

Since this approach may use patient's own cells to prepare cellular therapeutics and is based on non-toxic immunotherapy, it holds potential for translation to clinical application and may be particularly valuable as a new type of anti-metastatic cancer therapy.

With the increasing potential of using EPCs as cancer therapeutics, it is important to have a reliable and stable supply of human EPCs, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. This study demonstrates the feasibility of generating EPs from early-passage human iPS cells.

###

Link:
New Stem Cell Production Method Could Clear Way for Anticancer Gene Therapy

RIKEN press release: Pushing cells towards a higher pluripotency state

PUBLIC RELEASE DATE:

24-Jun-2014

Contact: Jens Wilkinson jens.wilkinson@riken.jp RIKEN

Stem cells have the unique ability to become any type of cell in the body. Given this, the possibility that they can be cultured and engineered in the laboratory makes them an attractive option for regenerative medicine. However, some conditions that are commonly used for culturing human stem cells have the potential to introduce contaminants, thus rendering the cells unusable for clinical use. These conditions cannot be avoided, however, as they help maintain the pluripotency of the stem cells.

In a study published in Scientific Reports, a group from the RIKEN Center for Life Science Technologies in Japan has gained new insight into the role of CCL2, a chemokine known to be involved in the immune response, in the enhancement of stem cell pluripotency. In the study, the researchers replaced basic fibroblast growth factor (bFGF), a critical component of human stem cell culture, with CCL2 and studied its effect. The work showed that CCL2 used as a replacement for bFGF activated the JAK/STAT pathway, which is known to be involved in the immune response and maintenance of mouse pluripotent stem cells. In addition, the cells cultured with CCL2 demonstrated a higher tendency of colony attachment, high efficiency of cellular differentiation, and hints of X chromosome reactivation in female cells, all markers of pluripotency.

To understand the global effects of CCL2, the researchers compared the transcriptome of stem cells cultured with CCL2 and those with bFGF. They found that stem cells cultured with CCL2 had higher expression of genes related to the hypoxic response, such as HIF2A (EPAS1). The study opens up avenues for further exploring the relationship between cellular stress, such as hypoxia, and the enhancement of pluripotency in cells. Yuki Hasegawa of CLST, who led the study, says, "Among the differentially expressed genes, we found out that the most significantly differentially expressed ones were those related to hypoxic responses, and hypoxia is known to be important in the progression of tumors and the maintenance of pluripotency. These results could potentially contribute to greater consistency of human induced pluripotent stem cells (iPSCs), which are important both for regenerative medicine and for research into diseases processes."

As a way to apply CCL2 towards the culturing of human iPSCs with more consistent quality, the researchers developed dishes coated with CCL2 and LIF protein beads. This allowed stem cells to be cultured in a feeder-free condition, preventing the risk that viruses or other contaminants could be transmitted to the stem cells. While the exact mechanisms of how CCL2 enhances pluripotency has yet to be elucidated, this work highlights the usefulness of CCL2 in stem cell culture.

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Link:
RIKEN press release: Pushing cells towards a higher pluripotency state

Scientists identify link between stem cell regulation and the development of lung cancer

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles

UCLA researchers led by Dr. Brigitte Gomperts have discovered the inner workings of the process thought to be the first stage in the development of lung cancer. Their study explains how factors that regulate the growth of adult stem cells that repair tissue in the lungs can lead to the formation of precancerous lesions.

Findings from the three-year study could eventually lead to new personalized treatments for lung cancer, which is responsible for an estimated 29 percent of U.S. cancer deaths, making it the deadliest form of the disease.

The study was published online on June 19 in the journal Stem Cell. Gomperts, a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the UCLA Jonsson Comprehensive Cancer Center, collaborated with Manash Paul and Bharti Bisht, postdoctoral scholars and co-lead authors of the study.

Adult stem cells in lung airways are present specifically to repair the airways after injury or disease caused by smoking, pollution, viruses or other factors. Gomperts and her team found that this reparative process is tightly regulated by molecules called reactive oxygen species, or ROS.

Recent research has shown that low levels of ROS are important for signaling the stem cells to perform important functions such as repairing tissue damage while high levels of ROS can cause stem cells to die. But the level of ROS needed for repair to be initiated has remained a subject of debate among researchers.

The UCLA study found that the dynamic flux of ROS from low to moderate levels in the airway stem cells is what drives the repair process, and that the increase in ROS levels in the repairing cell is quickly reduced to low levels to prevent excessive cell proliferation.

Gomperts' lab found that disrupting this normal regulation of ROS back to low levels is equivalent to pulling the brakes off of the stem cells: They will continue to make too many of themselves, which causes the cells not to mature and instead become precancerous lesions. Subsequent progressive genetic changes to the cells in these lesions over time can eventually allow cancerous tumors to form.

Continue reading here:
Scientists identify link between stem cell regulation and the development of lung cancer

Windows bug-testing software cracks stem cell programs

SOFTWARE used to keep bugs out of Microsoft Windows programs has begun shedding light on one of the big questions in modern science: how stem cells decide what type of tissue to become.

Not only do the results reveal that cellular decision-making is nowhere near as complicated as expected, they also raise hopes that the software could become a key tool in regenerative medicine.

"It is a sign of the convergence between carbon and silicon-based life," says Chris Mason, a regenerative medicine specialist at University College London. "World-class stem cell scientists and a world-class computer company have found common ground. It is work at such interfaces that brings the big breakthroughs."

Stem cells are the putty from which all tissues of the body are made. That means they have the potential to repair damaged tissue and even grow into new organs.

Embryonic stem cells hold particular promise as they can either renew themselves indefinitely or differentiate into any kind of cell in the body a property known as pluripotency.

The process that sets a stem cell on the path to either self-renewal or differentiation was thought to be a highly complex web of genetic and environmental interactions. That web is known as the interactome.

Embryonic stem cells are currently being trialled as a way to restore vision and treat spinal injury. But these trials, and others in the pipeline, are hampered by the fact that no one really knows what determines the fate of any particular stem cell. Today's techniques for making a stem cell differentiate into a certain tissues are hit-and-miss, says Mason.

What's needed is a more deterministic, reliable method, says Sara-Jane Dunn, a computational biologist at Microsoft Research in Cambridge. One approach is to frame the problem in the language of computation. The genetic and environmental cues that determine the cell's fate can be thought of as inputs, with the cell itself as the processor, Dunn says.

Stem cells' capacity to renew themselves is the simplest of the two possible paths out of the pluripotent state. To find the program behind this, Dunn, along with stem cell scientists Graziano Martello at the University of Padua in Italy, and Austin Smith at the University of Cambridge, tried to isolate the genetic and environmental processes at work in mouse embryonic stem cells.

They used a technique pioneered at Smith's lab that uses cultures of various inhibitory proteins to keep embryonic stem cells continually renewing themselves rather than differentiating into other cells. The team immersed the stem cells in four different types of these cultures and analysed which genes they expressed in which environment, and to what extent.

Original post:
Windows bug-testing software cracks stem cell programs

Researchers use human stem cells to create light-sensitive retina in a dish

PUBLIC RELEASE DATE:

10-Jun-2014

Contact: Lauren Nelson lnelso35@jhmi.edu 410-955-8725 Johns Hopkins Medicine

Using a type of human stem cell, Johns Hopkins researchers say they have created a three-dimensional complement of human retinal tissue in the laboratory, which notably includes functioning photoreceptor cells capable of responding to light, the first step in the process of converting it into visual images.

"We have basically created a miniature human retina in a dish that not only has the architectural organization of the retina but also has the ability to sense light," says study leader M. Valeria Canto-Soler, Ph.D., an assistant professor of ophthalmology at the Johns Hopkins University School of Medicine. She says the work, reported online June 10 in the journal Nature Communications, "advances opportunities for vision-saving research and may ultimately lead to technologies that restore vision in people with retinal diseases."

Like many processes in the body, vision depends on many different types of cells working in concert, in this case to turn light into something that can be recognized by the brain as an image. Canto-Soler cautions that photoreceptors are only part of the story in the complex eye-brain process of vision, and her lab hasn't yet recreated all of the functions of the human eye and its links to the visual cortex of the brain. "Is our lab retina capable of producing a visual signal that the brain can interpret into an image? Probably not, but this is a good start," she says.

The achievement emerged from experiments with human induced pluripotent stem cells (iPS) and could, eventually, enable genetically engineered retinal cell transplants that halt or even reverse a patient's march toward blindness, the researchers say.

The iPS cells are adult cells that have been genetically reprogrammed to their most primitive state. Under the right circumstances, they can develop into most or all of the 200 cell types in the human body. In this case, the Johns Hopkins team turned them into retinal progenitor cells destined to form light-sensitive retinal tissue that lines the back of the eye.

Using a simple, straightforward technique they developed to foster the growth of the retinal progenitors, Canto-Soler and her team saw retinal cells and then tissue grow in their petri dishes, says Xiufeng Zhong, Ph.D., a postdoctoral researcher in Canto-Soler's lab. The growth, she says, corresponded in timing and duration to retinal development in a human fetus in the womb. Moreover, the photoreceptors were mature enough to develop outer segments, a structure essential for photoreceptors to function.

Retinal tissue is complex, comprising seven major cell types, including six kinds of neurons, which are all organized into specific cell layers that absorb and process light, "see," and transmit those visual signals to the brain for interpretation. The lab-grown retinas recreate the three-dimensional architecture of the human retina. "We knew that a 3-D cellular structure was necessary if we wanted to reproduce functional characteristics of the retina," says Canto-Soler, "but when we began this work, we didn't think stem cells would be able to build up a retina almost on their own. In our system, somehow the cells knew what to do."

Read this article:
Researchers use human stem cells to create light-sensitive retina in a dish

Team applies new theory to learn how and why cells differentiate

Jun 16, 2014 An overview of the stem cell gene network gives a sense of the complex process involved in cell differentiation, as transcription factors and protein complexes influence and loop back upon each other. Rice University researchers found that stem cell differentiation can be defined as a many-body problem as they developed a theoretical system to analyze large gene networks. Credit: Bin Zhang/Rice University

How does a stem cell decide what path to take? In a way, it's up to the wisdom of the crowd.

The DNA in a pluripotent stem cell is bombarded with waves of proteins whose ebb and flow nudge the cell toward becoming blood, bone, skin or organs. A new theory by scientists at Rice University shows the cell's journey is neither a simple step-by-step process nor all random.

Theoretical biologist Peter Wolynes and postdoctoral fellow Bin Zhang set out to create a mathematical tool to analyze large, realistic gene networks. As a bonus, their open-access study to be published this week by the Proceedings of the National Academy of Sciences helped them understand that the process by which stem cells differentiate is a many-body problem.

"Many-body" refers to physical systems that involve interactions between large numbers of particles. Scientists assume these many bodies conspire to have a function in every system, but the "problem" is figuring out just what that function is. In the new work, these bodies consist not only of the thousands of proteins expressed by embryonic stem cells but also DNA binding sites that lead to feedback loops and other "attractors" that prompt the cell to move from one steady state to the next until it reaches a final configuration.

To test their tool, the researchers looked at the roles of eight key proteins and how they rise and fall in number, bind and unbind to DNA and degrade during stem cell differentiation. Though the interactions may not always follow a precise path, their general pattern inevitably leads to the desired result for the same reason a strand of amino acids will inevitably fold into the proper protein: because the landscape dictates that it be so.

Wolynes called the new work a "stylized," simplified model meant to give a general but accurate overview of how cell networks function. It's based on a theory he formed in 2003 with Masaki Sasai of Nagoya University but now takes into account the fact that not one but many genes can be responsible for even a single decision in a cellular process.

"This is what Bin figured out, that one could generalize our 2003 model to be much more realistic about how several different proteins bind to DNA in order to turn it on or off," Wolynes said.

A rigorous theoretical approach to determine the transition pathways and rates between steady states was also important, Zhang said. "This is crucial for understanding the mechanism of how stem cell differentiation occurs," he said.

Wolynes said that because the stem cell is stochasticthat is, its fate is not pre-determined"we had to ask why a gene doesn't constantly flip randomly from one state to another state. This paper for the first time describes how we can, for a pretty complicated circuit, figure out there are only certain periods during which the flipping can occur, following a well-defined transition pathway."

Read the rest here:
Team applies new theory to learn how and why cells differentiate

Scientists create an 'eye-in-a-dish' using human stem cells

Scientists copied processes that occur in the womb to create eye tissue Study used adult stem cells that have been genetically reprogrammed Lab-grown tissue responded to light the same way as it does in the eye The study represents a first step towards restoring sight in the blind

By Ellie Zolfagharifard

Published: 12:14 EST, 10 June 2014 | Updated: 14:02 EST, 10 June 2014

688 shares

5

View comments

A light-sensitive 'eye-in-a-dish' has been created by scientists using a type of human stem cell.

The three dimensional structure represents a first step towards restoring sight to the blind, say the researchers.

Processes that occur in the womb were copied to create complex retinal tissue in a laboratory petri dish.

A light-sensitive 'eye-in-a-dish' has been created by scientists in Maryland. The three dimensional structure represents a first step towards restoring sight to the blind, say the researchers. Pictured are the photoreceptors (in green) within a 'mini retina' structure (blue) that was created using human stem cells

Read more:
Scientists create an 'eye-in-a-dish' using human stem cells

Mount Sinai Researchers Identify Protein That Keeps Blood Stem Cells Healthy as They Age

Contact Information

Available for logged-in reporters only

Newswise (New York June 9, 2014) -- A protein may be the key to maintaining the health of aging blood stem cells, according to work by researchers at the Icahn School of Medicine at Mount Sinai recently published online in Stem Cell Reports. Human adults keep stem cell pools on hand in key tissues, including the blood. These stem cells can become replacement cells for those lost to wear and tear. But as the blood stem cells age, their ability to regenerate blood declines, potentially contributing to anemia and the risk of cancers like acute myeloid leukemia and immune deficiency. Whether this age-related decline in stem cell health is at the root of overall aging is unclear.

The new Mount Sinai study reveals how loss of a protein called Sirtuin1 (SIRT1) affects the ability of blood stem cells to regenerate normally, at least in mouse models of human disease. This study has shown that young blood stem cells that lack SIRT1 behave like old ones. With use of advanced mouse models, she and her team found that blood stem cells without adequate SIRT1 resembled aged and defective stem cells, which are thought to be linked to development of malignancies.

"Our data shows that SIRT1 is a protein that is required to maintain the health of blood stem cells and supports the possibility that reduced function of this protein with age may compromise healthy aging," says Saghi Ghaffari, MD, PhD, Associate Professor of Developmental and Regenerative Biology at Mount Sinai's Black Family Stem Cell Institute, Icahn School of Medicine. "Further studies in the laboratory could improve are understanding between aging stem cells and disease."

Next for the team, which includes Pauline Rimmel, PhD, is to investigate whether or not increasing SIRT1 levels in blood stem cells protects them from unhealthy aging or rejuvenates old blood stem cells. The investigators also plan to look at whether SIRT1 therapy could treat diseases already linked to aging, faulty blood stem cells.

They also believe that SIRT1 might be important to maintaining the health of other types of stem cells in the body, which may be linked to overall aging.

The notion that SIRT1 is a powerful regulator of aging has been highly debated, but its connection to the health of blood stem cells "is now clear," says Dr. Ghaffari. "Identifying regulators of stem cell aging is of major significance for public health because of their potential power to promote healthy aging and provide targets to combat diseases of aging," Dr. Ghaffari says.

Researchers from Harvard Medical School and Children's Hospital in Boston participated in the study.

About the Mount Sinai Health System The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient servicesfrom community-based facilities to tertiary and quaternary care.

Here is the original post:
Mount Sinai Researchers Identify Protein That Keeps Blood Stem Cells Healthy as They Age